Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy AC Immune stock

Learn how to easily invest in AC Immune stock.

AC Immune Ltd is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in AC Immune

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACIU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

AC Immune stock price (NASDAQ: ACIU)

Use our graph to track the performance of ACIU stocks over time.

AC Immune shares at a glance

Information last updated 2022-09-26.
Latest market close$2.52
52-week range$2.06 - $8.14
50-day moving average $3.14
200-day moving average $3.77
Wall St. target price$10.60
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.00

Buy AC Immune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AC Immune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AC Immune price performance over time

Historical closes compared with the close of $2.52 from 2022-09-27

1 week (2022-09-22) -2.70%
1 month (2022-08-29) -21.00%
3 months (2022-06-29) -30.58%
6 months (2022-03-29) -43.88%
1 year (2021-09-29) -63.16%
2 years (2020-09-29) -47.61%
3 years (2019-09-27) 4.94
5 years (2017-09-29) 11.17

AC Immune financials

Revenue TTM $944,000
Gross profit TTM $-62,282,000
Return on assets TTM -23.89%
Return on equity TTM -38.6%
Profit margin 0%
Book value $2.40
Market capitalisation $200.2 million

TTM: trailing 12 months

AC Immune share dividends

We're not expecting AC Immune to pay a dividend over the next 12 months.

AC Immune share price volatility

Over the last 12 months, AC Immune's shares have ranged in value from as little as $2.06 up to $8.14. A popular way to gauge a stock's volatility is its "beta".

ACIU.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.7131. This would suggest that AC Immune's shares are less volatile than average (for this exchange).

AC Immune overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.

Frequently asked questions

What percentage of AC Immune is owned by insiders or institutions?
Currently 52.064% of AC Immune shares are held by insiders and 18.23% by institutions.
When does the fiscal year end for AC Immune?
AC Immune's fiscal year ends in December.
Where is AC Immune based?
AC Immune's address is: Building B, Lausanne, Switzerland, 1015
What is AC Immune's ISIN number?
AC Immune's international securities identification number is: CH0329023102
What is AC Immune's CUSIP number?
AC Immune's Committee on Uniform Securities Identification Procedures number is: H00263105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site